Global Data has released its new Country report, "PharmaPoint: Multiple Sclerosis - India Drug Forecast and Market Analysis to 2022". Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. https://www.reportscorner.com/reports/15505/PharmaPoint:-Multiple-Sclerosis---India-Drug-Forecast-and-Market-Analysis-to-2022/

1. RC
Reports Corner
PharmaPoint: Multiple Sclerosis - India Drug
Forecast and Market Analysis to 2022

2. DescriptionDescription
Reports Cornerwww.reportscorner.com
GlobalData has released its new Country report, "PharmaPoint:
Multiple Sclerosis - India Drug Forecast and Market Analysis to
2022". Multiple sclerosis (MS) is a chronic, inflammatory
neurological disorder characterized pathologically by
demyelination, axonal transection and neurodegeneration within
the central nervous system.

3. Brief SummaryBrief Summary
Reports Cornerwww.reportscorner.com
PharmaPoint: Multiple Sclerosis - India Drug Forecast and Market
Analysis to 2022
Summary
GlobalData has released its new Country report, "PharmaPoint:
Multiple Sclerosis - India Drug Forecast and Market Analysis to
2022". Multiple sclerosis (MS) is a chronic, inflammatory
neurological disorder characterized pathologically by
demyelination, axonal transection and neurodegeneration within
the central nervous system. With curative therapy still elusive,
current disease management is dependent on life-long
pharmacotherapy with disease-modifying therapies (DMT). The
dominance of first-line injectable DMTs, including the interferon
beta (IFNß) agents: Bayer’s Betaseron/Betaferon (IFNß-1b),
Biogen’s Avonex (IFNß-1a) and Merck’s Rebif (IFNß-1a), and
Teva’s Copaxone (glatiramer acetate), has been a salient feature
of the MS therapeutics market.

4. Brief SummaryBrief Summary
Reports Cornerwww.reportscorner.com
However, the competitive landscape is undergoing significant
change with the emergence of oral therapies, several pipeline
products with notable efficacies, and looming
generics/biosimilars following the patent expiries of key branded
products during the forecast period. In addition, the entry of new
companies such as Sanofi/Genzyme and F. Hoffmann-La-
Roche/Genentech will challenge the position of the established
players in the MS marketplace.
MS has a low prevalence in India, which could be due to genetics
or environmental factors. However, many physicians surveyed for
this report mostly use the Poser criteria to diagnose patients,
given the lack of current accessibility to sensitive diagnostic
tools, such as MRI. Therefore, it is possible that the current rate of
MS in India is grossly underestimated, meaning a large proportion
of undiagnosed MS patients are not captured and provided
adequate treatment.

5. Brief SummaryBrief Summary
Reports Cornerwww.reportscorner.com
The major drivers of growth in this market will be the launch of
oral DMTs and an increase in availability of advanced diagnostic
tools, which will likely lead to increased diagnosis and treatment
rates over the forecast period.
Note: This is upcoming report and will be delivered within 24 hrs
of the purchase (excluding weekends).
Scope
- Overview of the Multiple Sclerosis including epidemiology,
etiology, symptoms, diagnosis, pathology and treatment
guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in India including product
description, safety and efficacy profiles as well as a SWOT
analysis.

6. Brief SummaryBrief Summary
Reports Cornerwww.reportscorner.com
- Sales forecast for the top drugs in India from 2012-2022.
- Analysis of the impact of key events as well the drivers and
restraints affecting India Multiple Sclerosis market.
Reasons to buy
- Understand and capitalize by identifying products that are most
likely to ensure a robust return
- Stay ahead of the competition by understanding the changing
competitive landscape for Multiple Sclerosis
- Effectively plan your M&A and partnership strategies by
identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-
depth analysis of drug performance
- Obtain sales forecast for drugs from 2012-2022 in India

7. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
1 Table of Contents 4
1.1 List of Tables 8
1.2 List of Figures 10
2 Introduction 11
2.1 Catalyst 11
2.2 Related Reports 12
2.3 Upcoming Related Reports 13
3 Disease Overview 14
3.1 Etiology and Pathophysiology 14
3.1.1 Etiology 14
3.1.2 Pathophysiology 15
3.1.3 Classification of Multiple Sclerosis 16
3.2 Symptoms 18
3.2.1 Prognosis 19
3.2.2 Quality of Life 20

8. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
4 Disease Management 21
4.1 Diagnosis 21
4.2 Treatment Overview 24
4.2.1 Management of Acute Relapse 25
4.2.2 Treatment with Disease-Modifying Therapies 25
4.2.3 Symptomatic Therapies 28
4.3 India 29
4.3.1 Diagnosis 29
4.3.2 Clinical Practice 29
5 Competitive Assessment 31
5.1 Overview 31
5.2 Strategic Competitor Assessment 32
5.3 Product Profiles – Major Brands 33
5.3.1 Betaseron/Betaferon (interferon beta-1b) 33
5.3.2 Avonex

9. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
5.3.2 Avonex (interferon beta-1a) 37
5.3.3 Rebif (interferon beta-1a) 42
5.3.4 Copaxone (glatiramer acetate; copolymer-1) 46
5.3.5 Tysabri (natalizumab) 50
5.3.6 Gilenya/Imusera (fingolimod; FTY720) 54
5.3.7 Aubagio (teriflunomide) 59
5.3.8 Other Disease–Modifying Therapies 63
6 Opportunity and Unmet Need 64
6.1 Overview 64
6.2 Unmet Needs 65
6.2.1 Currently Available MS Drugs Only Provide Partial Benefits 65
6.2.2 The High Cost of MS Drugs Could Continue to Price out Patients 66
6.2.3 Effective Treatments for Progressive MS Are Still Elusive 67
6.2.4 Inconvenient Route of Administration and Frequent Dosing Limits Compliance 68
6.2.5 The Lack of Predictive Biomarkers Delays MS Diagnosis 69

10. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
6.3 Unmet Needs Gap Analysis 69
6.4 Opportunities 70
6.4.1 Treatments for Progressive MS 70
6.4.2 Targeting Patients with Clinically Isolated Syndrome 71
7 Pipeline Assessment 72
7.1 Overview 72
7.2 Promising Drugs in Clinical Development 73
7.2.1 BG-12 (dimethyl fumarate; BG00012) 76
7.2.2 Lemtrada (alemtuzumab) 80
7.2.3 Laquinimod (ABR-215062) 85
7.2.4 Daclizumab High-Yield Process (HYP) 90
7.2.5 Ocrelizumab (RG1594) 94
7.2.6 Siponimod (BAF-312) 98
7.2.7 NU-100 (interferon beta-1b) 102
7.2.8 Masitinib (AB-1010) 105

11. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
7.2.9 Tcelna (imilecleucel-T) 108
8 Market Outlook 113
8.1 India 113
8.1.1 Forecast 113
8.1.2 Key Events 115
8.1.3 Drivers and Barriers 116
9 Appendix 118
9.1 Bibliography 118
9.2 Abbreviations 129
9.3 Methodology 133
9.4 Forecasting Methodology 133
9.4.1 Diagnosed MS patients 133
9.4.2 Percent Drug-Treated Patients 133
9.4.3 Drugs Included in Each Therapeutic Class 134
9.4.4 General Pricing Assumptions 134

12. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
9.4.5 Individual Drug Assumptions 135
9.4.6 Generic Erosion 139
9.4.7 Pricing of Pipeline agents 139
9.5 Physicians and Specialists Included in This Report 140
9.6 Primary Research – Prescriber Survey 141
9.7 About the Authors 142
9.7.1 Analysts 142
9.7.2 Global Head of Healthcare 143
9.8 About GlobalData 144
9.9 Contact Us 144
9.10 Disclaimer 144

13. For more informationFor more information
Reports Cornerwww.reportscorner.com
For more information please visit our website
https://www.reportscorner.com/reports/15505/PharmaPoint:-Multiple-Sclerosis---
India-Drug-Forecast-and-Market-Analysis-to-2022/

14. Reports Corner
Thank YouThank You
www.reportscorner.com
RC
Contact us: contact@reportscorner.com